Optimizing Care in Relapsed/Refractory (R/R)
Chronic Lymphocytic Leukemia (CLL):
Practical Approaches to Challenging Decisions
Friday, October 10th 2025
13:40 – 15:10 CEST (UTC +2)
Hall A, Pullman Paris Tour Eiffel, Paris, France
Center Léon Bérard,
Lyon, France
CHAIR
University Campus
Bio-Medico of Rome
Rome, Italy
Harold C. Simmons
Comprehensive
Cancer Center,
University of Texas
Southwestern Medical
Center
Texas, USA
National and Kapodistrian
University of Athens
Athens, Greece
| Agenda | |||
|---|---|---|---|
| 13:40–13:45 | Welcome and introduction Chair: Dr. Anne-Sophie Michallet |
||
| 13:45–14:05 | How do BTK inhibitors work and how do they differ from each other? Prof. Giorgio Minotti Q&A |
||
| 14:05–14:15 | Sequencing in post-cBTKi CLL: What does the clinical trial data tell us? Prof. Farrukh Awan |
||
| 14:15–14:30 | Clinical case discussion 1 Prof. Farrukh Awan |
||
| 14:30–14:40 | Sequencing in post-cBTKi CLL: What does the real-world evidence tell us? Asst. Prof. Maria Dimou |
||
| 14:40–14:55 | Clinical case discussion 2 Asst. Prof. Maria Dimou |
||
| 14:55–15:05 | Panel discussion and Q&A All speakers |
||
| 15:05–15:10 | Conclusion and closing remarks Chair: Dr. Anne-Sophie Michallet |
||
BTK: Bruton’s tyrosine kinase; cBTKi: covalent Bruton’s Tyrosine Kinase inhibitor; CEST: Central European Summer Time; CLL: Chronic Lymphocytic Leukemia; IACH: International Academy of Clinical Hematology; R/R: Relapsed Refractory; UTC: Universal Time Coordinated.
08/2025. © 2025 Lilly, LLC. All rights reserved.